

Ref: MHL/Sec&Legal/2025-26/33

July 04, 2025

To,
BSE Limited
Scrip Code: 542650

National Stock Exchange of India Ltd.
Scrip Symbol: METROPOLIS

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Code of Fair Disclosure of Unpublished Price Sensitive Information & Policy for Legitimate Purpose in terms of Regulation 8 of the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has provided a business update for the quarter ended June 30, 2025.

This update seeks to provide an overall summary of the operating performance and demand trends witnessed during the quarter ended June 30, 2025. A detailed information update will follow once the Board of Directors approves the financial results for Q1FY26.

While the healthcare industry experienced a surprising slowdown in Q4FY25, it appears to be a seasonal and not a structural issue in the industry. The April to June period has marked a return to normalized activity. Competition dynamics remains unchanged, and we continue to believe that Metropolis has the ability to keep growing well organically on the back of patients who need quality results for critical illness. Integrations of recent acquisitions are progressing as planned.

Key highlights of Q1FY26 (Consolidated):

1. Revenue growth is approx. **23%** on a Y-o-Y basis including revenues from Core Diagnostics (**Core**) (full quarter), Scientific Pathology (**Scientific**), Agra (consolidated from 17th June, 2025) and Dr. Ahuja's Pathology & Imaging Center (**DAPIC**), Dehradun (consolidated from 23rd May, 2025).
2. Post-acquisition, Core has moved from breakeven position in Q4FY25 to a single digit positive margin trajectory, while DAPIC, Dehradun and Scientific, Agra outperformed the company average on margin performance. On a consolidated level, MHL EBIDTA margin percentage is slightly lower due to consolidation of Core.
3. Specialty revenues witness a growth of approx. **35%+** on a Y-o-Y basis on account of consolidation of Core which is largely high-end specialized Oncology Testing.

Key highlights of Q1FY26 (Excluding acquisition of Core, DAPIC and Scientific):

1. Revenues grew by approximately **13%** Y-o-Y, driven by an increase in patient and test volumes, a favorable shift in product mix, and improved realizations.
2. B2C revenues registered a Y-o-Y growth of around **15%**.



3. The TruHealth Wellness and Specialty segments recorded Y-o-Y growth of **~20% and ~15%**, respectively, in Q1FY26.
4. EBITDA for the current quarter improved on a Q-o-Q on account of increased throughput, operational efficiencies and operating leverage and remained in line with the same period last year.
5. The Company is debt free.

The quarterly business update is on a consolidated basis. The financial results of Q1FY26 are subject to review by Auditors.

For **Metropolis Healthcare Limited**

Kamlesh C Kulkarni
Head – Legal & Secretarial

